Supplement aids age-related macular degeneration

Supplement aids age-related macular degeneration
A supplement containing a combination of lutein, zeaxanthin, and ω-3 long-chain polyunsaturated fatty acids significantly benefits patients with age-related macular degeneration, according to a study published online March 21 in JAMA Ophthalmology.

(HealthDay)—A supplement containing a combination of lutein, zeaxanthin, and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs) significantly benefits patients with age-related macular degeneration (AMD), according to a study published online March 21 in JAMA Ophthalmology.

Christin Arnold, from Friedrich Schiller University Jena in Thuringia, Germany, and colleagues randomized individuals with nonexudative AMD to either a ; group 1 (a capsule containing 10 mg of lutein, 1 mg of zeaxanthin, 100 mg of docosahexaenoic acid, and 30 mg of eicosapentaenoic acid administered each day); or group 2 (same substances but twice the dose used in group 1).

For the 145 participants completing the study, the researchers found that there were significant increases in plasma concentrations of the administered as well as the optical density of the macular pigment in the groups randomized to receive supplementary macular xanthophylls and ω-3 LC-PUFAs after one month of intervention. These increases remained at this level through the study duration. The double dose in group 2 resulted in a beneficial change in the fatty acid profile in the plasma of patients with AMD, compared to group 1. There was a significant elevation in the lipophilic in plasma with the intervention.

"A supplement containing a fixed combination of lutein, zeaxanthin, and ω-3 LC-PUFAs during 12 months significantly improved plasma antioxidant capacity, circulating macular xanthophyll levels, and the optical density of the macular pigment," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Findings support link between hsCRP, macular degeneration

Feb 08, 2013

(HealthDay)—Pooled results from five cohorts confirm that high levels of high-sensitivity C-reactive protein (hsCRP) correlate with increased future risk of age-related macular degeneration (AMD), according ...

Recommended for you

Multidose eye drop approach approved by joint commission

Dec 14, 2014

(HealthDay)—A policy and procedural approach to the use of multidose eye drops has been approved by The Joint Commission and can reduce costs for patients and facilities, according to an article published ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.